Teva Pharmaceuticals Stock Surges on New Drug Approvals and Financial Recovery

Teva Pharmaceuticals is undergoing a significant transformation, shifting from a company burdened by heavy debt and declining generic drug sales to one expanding its innovative drug portfolio and improving its financial standing. A new report from Leumi Capital Markets, authored by Head of Research Sabina Levy, has raised Teva's stock price target to $50, maintaining a "buy" recommendation. Key factors driving this optimism include regulatory approval for the drug Weltruza, strengthening business operations, and a return to investment-grade credit ratings from three major agencies.

The most significant development is the U.S. Food and Drug Administration's (FDA) approval of Weltruza, a treatment for adult schizophrenia based on the active ingredient olanzapine. Approved on October 9, 2026, this once-monthly subcutaneous injection offers a commercial advantage as it requires no post-injection monitoring, loading dose, or concurrent oral medication, potentially simplifying patient use and reducing clinic burdens. The drug targets the approximately 300,000 patients in the U.S. currently using oral olanzapine. Significant contributions to revenue from Weltruza are anticipated starting in the second half of 2027, pending insurance and Medicaid coverage approvals. Combined with the drug Uzedy, Teva aims for peak aggregate sales of $1.5 to $2 billion.

Other promising developments include positive Phase 2a trial results for the experimental celiac disease drug TEV-'408, which targets IL-15 and showed statistically significant improvements in reducing gut damage from gluten exposure. Additionally, Duvakitug, developed with Sanofi, is expected to advance to Phase 2 trials later this year for conditions like hidradenitis suppurativa and Crohn's disease. Ecopipam has received FDA fast-track designation for treating pediatric Tourette syndrome, with a decision expected in late Q1 2027 and a potential launch during that year.

Financially, Teva has regained investment-grade status with S&P (BBB), Fitch (BBB), and Moody's (Baa3), all with stable outlooks. The company also completed a $4.9 billion debt refinancing, extending its debt maturity and lowering financing costs. Teva's efficiency program is projected to yield $700 million in net savings by 2027, with two-thirds expected by 2026. The company is targeting a gross profit margin of 57%-58% and an operating profit margin of approximately 30% by 2027, with free cash flow exceeding $2.7 billion and a net debt to adjusted EBITDA ratio falling to 2.0.

Despite the positive outlook, the report notes short-term challenges, particularly in Q4 2026, where sales of Austedo may experience volatility due to inventory normalization and preparations for a new CMS agreement effective January 1, 2027. Annual sales forecasts for Austedo are $2.45-$2.60 billion, while Ajovy is projected at $850-$870 million and Uzedy at $270-$290 million. Generic and biosimilar revenues are expected to decline this year due to Revlimid erosion and the sale of its Japanese operations, though underlying business remains stable. Teva markets 15 biosimilar products and aims for over $800 million in biosimilar revenue by 2027. Teva's Q3 2026 earnings report is due November 3, with consensus estimates predicting $4.246 billion in revenue and $1.352 billion in adjusted EBITDA.